Analysts See $-1.63 EPS for Agios Pharmaceuticals, Inc. (AGIO)

October 14, 2018 - By Pete Kolinski

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment decreased to 1.48 in 2018 Q2. Its down 0.24, from 1.72 in 2018Q1. It worsened, as 16 investors sold Agios Pharmaceuticals, Inc. shares while 50 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.36 million shares or 1.07% less from 52.93 million shares in 2018Q1 were reported.
Cap Sarl owns 27,100 shares. North Star Asset Mgmt accumulated 5,600 shares or 0.04% of the stock. Credit Suisse Ag has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Citadel Lc, Illinois-based fund reported 3,501 shares. Castleark Management Limited Liability holds 0.25% or 96,330 shares. Creative Planning reported 4,681 shares. Bancorporation Of Mellon has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). 280,910 are held by Ubs Asset Mngmt Americas Inc. Parallax Volatility Advisers Lp reported 20,784 shares or 0% of all its holdings. Alliancebernstein Limited Partnership holds 24,672 shares. Massmutual Fsb Adv owns 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 5,082 shares. Ameriprise Financial has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Capital Interest Ca reported 15,300 shares. Daiwa Gp Inc stated it has 314 shares or 0% of all its holdings. Sei Invests Com has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 9,099 shares.

Since April 12, 2018, it had 0 insider purchases, and 21 sales for $17.57 million activity. Another trade for 13,000 shares valued at $1.08M was sold by Schenkein David P. Biller Scott sold $249,215 worth of stock. Bowden Christopher sold 2,000 shares worth $185,786. On Wednesday, May 23 Hoerter Steven L. sold $175,808 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,050 shares. $841,926 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Foster-Cheek Kaye I on Thursday, June 14. MARAGANORE JOHN sold $2.00 million worth of stock or 27,717 shares.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.63 EPS on November, 7.They anticipate $0.04 EPS change or 2.52 % from last quarter’s $-1.59 EPS. After having $-1.19 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see 36.97 % EPS growth. The stock increased 3.98% or $2.52 during the last trading session, reaching $65.88. About 532,248 shares traded or 47.52% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 12.19% since October 14, 2017 and is uptrending. It has underperformed by 3.43% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 5 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Agios Pharmaceuticals had 5 analyst reports since May 23, 2018 according to SRatingsIntel. The firm has “Hold” rating by Oppenheimer given on Monday, June 18. The company was initiated on Wednesday, May 30 by Piper Jaffray.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $3.82 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More news for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were recently published by: Seekingalpha.com, which released: “Premarket analyst action – healthcare” on September 25, 2018. Globenewswire.com‘s article titled: “New Research Coverage Highlights Camden Property Trust, Agios Pharmaceuticals, Crane, BorgWarner, Cognizant …” and published on October 04, 2018 is yet another important article.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>